GlassScriptPhysician profile
Misty Gilley
NPI 1891141529
$4,905.70
in general payments reported to CMS, 2019-2025
32 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,230 · 2022: $1,076 · 2023: $1,105 · 2024: $1,001 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,598.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $993.28 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $593.89 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $399.66 | 2022-2025 | |
| Amgen INC. | $365.12 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $359.74 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $338.59 | 2021 | |
| Lilly USA, LLC | $257.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $255.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.08 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $142.06 | 2021-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $120.93 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $101.97 | 2021-2022 | |
| Glaxosmithkline, LLC. | $91.24 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $90.67 | 2022-2025 | Spravato |
| Sumitomo Pharma America, INC. | $73.48 | 2023-2025 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $51.42 | 2022 | |
| Phathom Pharmaceuticals, INC. | $48.97 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $48.76 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $42.07 | 2025 | Auvelity |
| Radius Health, INC. | $38.29 | 2024-2025 | Tymlos |
| Bone Support INC. | $35.68 | 2025 | Cerament G, Ceramentbone Void Filler |
| Exact Sciences Corporation | $34.63 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $33.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.34 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.69 | 2022-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $28.23 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $28.15 | 2021 | |
| Alkermes, INC. | $20.49 | 2022 | |
| Abbott Laboratories | $19.68 | 2021 | |
| Merck Sharp & Dohme LLC | $17.19 | 2021 | |
| Lundbeck LLC | $17.17 | 2024 | Rexulti |
| Astellas Pharma US INC | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Gilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.